Wen Zeng1, Hanying Sun1, Fankai Meng1, Zeming Liu2, Jing Xiong3, Sheng Zhou3, Fan Li4, Jia Hu4, Zhiquan Hu4, Zheng Liu4. 1. Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China. 2. Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, China. 3. Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China. 4. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China.
Abstract
PURPOSE: Upregulation of nuclear C-MYC protein has been reported to be an early event in prostate cancer (PCa); however, its clinicopathological and prognostic significance remain controversial. We determined the association of nuclear C-MYC protein expression with clinicopathological parameters, prognosis, ETS-related gene (ERG) expression, and TMPRSS2-ERG status in PCa. METHODS: Nuclear C-MYC and ERG expression by immunohistochemistry and TMPRSS2-ERG status by triple-color probe fluorescence in situ hybridization assay were determined in 50 hormone-naïve PCa patients and 31 radical prostatectomy specimens. RESULTS: Nuclear C-MYC immunostaining was negative, positive, and strong positive in 27.5%, 32.5%, and 40.0% of cases, respectively. C-MYC immunostaining was significantly associated with clinical T stage (P < 0.001), distant metastasis at the time of diagnosis (P < 0.001) and TMPRSS2-ERG status (P = 0.001) but not with ERG immunostaining (P = 0.818). In the Kaplan-Meier analysis, C-MYC positive cases were found to have worse 2-year OS compared with C-MYC negative cases (P = 0.027). However, in the univariate Cox analysis, only TMPRSS2-ERG status (hazard ratio [HR] 0.189, 95% CI 0.057-0.629; P = 0.007) and distant metastasis (HR 3.545, 95% CI 1.056-11.894; P = 0.040) were significantly associated with 2-year OS. After adjusting for these two factors, TMPRSS2-ERG status still impacted 2-year OS (HR 0.196, 95% CI 0.049-0.778; P = 0.020). CONCLUSIONS: Nuclear C-MYC overexpression may be associated with disease progression and potentially predictive of 2-year OS in PCa. This is the first study to demonstrate an association between nuclear C-MYC immunostaining and TMPRSS2-ERG status in PCa.
PURPOSE: Upregulation of nuclear C-MYC protein has been reported to be an early event in prostate cancer (PCa); however, its clinicopathological and prognostic significance remain controversial. We determined the association of nuclear C-MYC protein expression with clinicopathological parameters, prognosis, ETS-related gene (ERG) expression, and TMPRSS2-ERG status in PCa. METHODS: Nuclear C-MYC and ERG expression by immunohistochemistry and TMPRSS2-ERG status by triple-color probe fluorescence in situ hybridization assay were determined in 50 hormone-naïve PCa patients and 31 radical prostatectomy specimens. RESULTS: Nuclear C-MYC immunostaining was negative, positive, and strong positive in 27.5%, 32.5%, and 40.0% of cases, respectively. C-MYC immunostaining was significantly associated with clinical T stage (P < 0.001), distant metastasis at the time of diagnosis (P < 0.001) and TMPRSS2-ERG status (P = 0.001) but not with ERG immunostaining (P = 0.818). In the Kaplan-Meier analysis, C-MYC positive cases were found to have worse 2-year OS compared with C-MYC negative cases (P = 0.027). However, in the univariate Cox analysis, only TMPRSS2-ERG status (hazard ratio [HR] 0.189, 95% CI 0.057-0.629; P = 0.007) and distant metastasis (HR 3.545, 95% CI 1.056-11.894; P = 0.040) were significantly associated with 2-year OS. After adjusting for these two factors, TMPRSS2-ERG status still impacted 2-year OS (HR 0.196, 95% CI 0.049-0.778; P = 0.020). CONCLUSIONS: Nuclear C-MYC overexpression may be associated with disease progression and potentially predictive of 2-year OS in PCa. This is the first study to demonstrate an association between nuclear C-MYC immunostaining and TMPRSS2-ERG status in PCa.
Entities:
Keywords:
C-MYC; ERG; TMPRSS2-ERG; immunohistochemistry; prostate cancer
Authors: Kasper Drimer Berg; Ben Vainer; Frederik Birkebæk Thomsen; M Andreas Røder; Thomas Alexander Gerds; Birgitte Grønkær Toft; Klaus Brasso; Peter Iversen Journal: Eur Urol Date: 2014-03-07 Impact factor: 20.096
Authors: Paula Paulo; João D Barros-Silva; Franclim R Ribeiro; João Ramalho-Carvalho; Carmen Jerónimo; Rui Henrique; Guro E Lind; Rolf I Skotheim; Ragnhild A Lothe; Manuel R Teixeira Journal: Genes Chromosomes Cancer Date: 2011-11-12 Impact factor: 5.006
Authors: D Hawksworth; L Ravindranath; Y Chen; B Furusato; I A Sesterhenn; D G McLeod; S Srivastava; G Petrovics Journal: Prostate Cancer Prostatic Dis Date: 2010-09-07 Impact factor: 5.554
Authors: Emmanuel S Antonarakis; Daniel Keizman; Zhe Zhang; Bora Gurel; Tamara L Lotan; Jessica L Hicks; Helen L Fedor; Michael A Carducci; Angelo M De Marzo; Mario A Eisenberger Journal: Cancer Date: 2012-06-06 Impact factor: 6.860
Authors: Jacques Lapointe; Chunde Li; Craig P Giacomini; Keyan Salari; Stephanie Huang; Pei Wang; Michelle Ferrari; Tina Hernandez-Boussard; James D Brooks; Jonathan R Pollack Journal: Cancer Res Date: 2007-09-15 Impact factor: 12.701
Authors: J R Gsponer; M Braun; V J Scheble; T Zellweger; A Bachmann; S Perner; T Vlajnic; M Srivastava; S H Tan; A Dobi; I A Sesterhenn; S Srivastava; L Bubendorf; C Ruiz Journal: Prostate Cancer Prostatic Dis Date: 2014-01-28 Impact factor: 5.554
Authors: C Sun; A Dobi; A Mohamed; H Li; R L Thangapazham; B Furusato; S Shaheduzzaman; S-H Tan; G Vaidyanathan; E Whitman; D J Hawksworth; Y Chen; M Nau; V Patel; M Vahey; J S Gutkind; T Sreenath; G Petrovics; I A Sesterhenn; D G McLeod; S Srivastava Journal: Oncogene Date: 2008-06-09 Impact factor: 9.867
Authors: Andreas Pettersson; Travis Gerke; Kathryn L Penney; Rosina T Lis; Edward C Stack; Nelma Pértega-Gomes; Giorgia Zadra; Svitlana Tyekucheva; Edward L Giovannucci; Lorelei A Mucci; Massimo Loda Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-15 Impact factor: 4.254
Authors: Sanjeev Shukla; Steven Fletcher; Jay Chauhan; Victor Chalfant; Carlos Riveros; Yuri Mackeyev; Pankaj Kumar Singh; Sunil Krishnan; Teruko Osumi; K C Balaji Journal: Cancer Gene Ther Date: 2022-04-19 Impact factor: 5.987